Researchers have developed the largest and most comprehensive molecular map to date of the lung cancer subtype lung squamous cell carcinoma (LSCC). Their effort brings proteomic, transcriptomic, and genomic data together into a detailed ‚proteogenomic‘ view of LSCC. Analysis of that data has revealed potential new drug targets, immune regulation pathways that might help the cancer evade immunotherapies, and even a new molecular subtype of LSCC.